Astrazeneca PLC (NYSE:AZN) shares gapped up prior to trading on Wednesday . The stock had previously closed at $30.26, but opened at $30.30. Astrazeneca PLC shares last traded at $30.62, with a volume of 4,371,415 shares traded.

Several brokerages have issued reports on AZN. Beaufort Securities reissued a “hold” rating on shares of Astrazeneca PLC in a research report on Tuesday. Shore Capital reaffirmed a “hold” rating on shares of Astrazeneca PLC in a research report on Wednesday. Bank of America Corp. reaffirmed a “buy” rating and set a $36.65 price objective on shares of Astrazeneca PLC in a research report on Monday. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Astrazeneca PLC in a research report on Thursday, April 21st. Finally, Jefferies Group reaffirmed a “hold” rating on shares of Astrazeneca PLC in a research report on Wednesday, April 20th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $562.78.

The firm has a market capitalization of $77.34 billion and a P/E ratio of 26.58. The stock’s 50-day moving average price is $29.31 and its 200-day moving average price is $29.60.

Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings results on Friday, April 29th. The company reported $0.51 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.60 by $0.09. During the same quarter last year, the business posted $1.08 EPS. The business earned $6.12 billion during the quarter, compared to the consensus estimate of $5.96 billion. Astrazeneca PLC’s revenue for the quarter was up 1.0% compared to the same quarter last year. On average, equities analysts expect that Astrazeneca PLC will post $2.36 earnings per share for the current year.

A number of large investors recently modified their holdings of the company. US Bancorp DE increased its stake in shares of Astrazeneca PLC by 8.2% in the fourth quarter. US Bancorp DE now owns 126,767 shares of the company’s stock valued at $4,304,000 after buying an additional 9,638 shares during the period. Bailard Inc. bought a new stake in shares of Astrazeneca PLC during the fourth quarter valued at $3,402,000. Burney Co. increased its stake in shares of Astrazeneca PLC by 3.5% in the fourth quarter. Burney Co. now owns 130,492 shares of the company’s stock valued at $4,448,000 after buying an additional 4,381 shares during the period. Wells Fargo & Company MN increased its stake in shares of Astrazeneca PLC by 7.6% in the fourth quarter. Wells Fargo & Company MN now owns 2,009,893 shares of the company’s stock valued at $68,236,000 after buying an additional 141,767 shares during the period. Finally, Morgan Stanley increased its stake in shares of Astrazeneca PLC by 16.3% in the fourth quarter. Morgan Stanley now owns 1,572,388 shares of the company’s stock valued at $53,382,000 after buying an additional 220,787 shares during the period.

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.